Drug Profile
KB ND 002
Alternative Names: KB-ND-002Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Krisani Biosciences
- Class
- Mechanism of Action Transglutaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Huntington's-disease in India
- 12 Aug 2016 Preclinical trials in Huntington's disease in India (unspecified route)